2023年8月27日 · 本研究发现， 99m Tc-RGD 可显著上调肿瘤细胞表面 PD-L1 表达水平；以 MC38 肿瘤鼠为模型， 18.5 MBq 或 37 MBq 99m Tc-RGD 联合α PD-L1 抗体在间隔 4 h 时间窗时可产生最佳抗肿瘤效果。

结果 经99mTc⁃RGD诱导后，CT26、MC38、4T1和B16F10肿瘤细胞表面的 PD⁃L1表达水平均显著上调，差异具有显著统计学意义（P均＜0 01）；以MC38肿瘤鼠为模型，对其注射 99m Tc⁃RGD并

Healthy MC38 tumor-bearing female C57BL/6 mice were intravenously injected with 17-18 MBq of either 177 Lu-EB-RGD (n = 4) or 177 Lu-RGD (n = 4). Whole body SPECT images were acquired at 4, 24, 48, 72, and 96 hours post injection (p.i.).

2024年1月26日 · In our pursuit of enhancing tumor uptake and retention, we designed and developed a novel peptidic heterodimer that synergistically targets both FAP and integrin α v β 3. FAP-RGD was synthesized from FAP-2286 and c (RGDfK) through a multi-step organic synthesis.

2024年6月18日 · Internalizing RGD (iRGD, c(CRGDKGPDC)), a promising tool in targeted drug delivery, operates through binding to αv integrins on tumor vasculature, facilitating extravasation into the tumor tissue. 16 Subsequently, proteolytic cleavage exposes a CendR motif (CRGDK), allowing iRGD to interact with neuropilin-1 (NRP-1) on both tumor and ...

在此基础上，本研究团队进一步探索了177Lu-DOTA-EB-cRGDfK（177Lu-DER）联合治疗的给药策略，在体内外证明了放射性核素刺激后PD-L1表达呈时间及剂量依赖性上调，在TRT后4 h通过尾静脉注射PD-L1抗体能够大大提高联合治疗的疗效，联合治疗组小鼠血清促炎细胞因子、CTLs及CD4+辅助T细胞（helper T cells, Th1）浸润增加，肿瘤完全缓解并获得特异性免疫记忆效应[31]。 随后用64Cu-DOTA-EB-cRGDfK（64Cu-DER）验证了该给药策略的有效性，提示该策略可推 …

In this study, we used a novel, easy and straightforward approach to generate engineered Salmonella ΔppGpp strains displaying the arginine-glycine-aspartate (RGD) peptide on the outer membrane protein A (OmpA).

2023年3月29日 · Truncated tissue factor–Arg-Gly-Asp (RGD) (tTF-RGD), administered either by intravenous (i.v.) or p.t. routes, targets tumor neovasculature endothelial cells and initiates coagulation cascade to recruit anti–programmed cell death 1 (PD-1) antibody–conjugated platelets (P-aPD-1).

MC-38 Cell Line derived from C57BL6 murine colon adenocarcinoma cells. From the laboratories of James W. Hodge, PhD, MBA and Jeffrey Schlom, PhD, National Cancer Institute/NIH. This product is for sale to Nonprofit customers only. For profit …

2023年4月12日 · 与不含 HAase 的非靶向 IONP 相比，c (RGDyK)-HAase-IONP 在 MC38 荷瘤小鼠模型中静脉注射后显示出更好的肿瘤靶向效果（高 2.5 倍），这是通过全身荧光成像确定的。 5 次全身治疗后，c (RGDyK)-HAase-IONP/DOX（5 mg/kg 等效剂量的 DOX）显着抑制 MC38 肿瘤生长（相对于未治疗组为 22.1 ± 7.4 倍）。 与对照组相比，在 c (RGDyK)-HAase-IONP/DOX 处理的肿瘤中检测到肿瘤细胞凋亡增加和增殖减少。 总体而言，高效靶向纳米载体 c (RGDyK) …